Read later
  • 11 Jan 2022

Loftware purchases Prisym ID

Loftware has acquired Prisym ID to expand its enterprise labeling offering for the medical device and pharmaceutical industries

Loftware has acquired Prisym ID to expand its enterprise labeling offering for the medical device and pharmaceutical industries while enhancing end-to-end cloud-based platform by adding advanced clinical trial labeling and regulated content management capabilities.

Building on Prisym ID’s industry focus, Loftware will offer customers new levels of innovation to help enable compliance through accurate, validation-ready labeling technologies and regulated product content while also growing the Loftware platform and offering more services to these strategic markets. 

The acquisition adds clinical trials technologies to Loftware’s existing enterprise labeling and artwork management platform. It is also expected to help customers tackle the challenges of clinical trial labeling, performed either in-house, through Clinical Research Organizations (CRO), or Clinical Development & Manufacturing Organizations (CDMO). 

‘This acquisition builds on Loftware’s and Prisym ID’s experience and unites the best talent in the medical device and pharmaceutical labeling industry today. Combined, we serve many of the largest global companies with solutions, services, and support that are vital to managing labeling complexities and regulatory requirements,’ said Robert O’Connor Jr., president and CEO of Loftware. ‘Prisym ID is a pioneer in clinical trials labeling and delivers solutions that are purpose-built for managing the nuances of this space. We will enable customers to tackle the complex challenges around clinical trial labeling and help them with the ability to quickly and efficiently complete trials.’

‘Together with Loftware, we can offer new levels of innovation which will further accelerate momentum in serving our customers and market. We’ll also be expanding our global presence and increasing our service and support resources to better serve our customers and meet increasing demands,’ added Richard Adams, CEO of Prisym ID. ‘By combining the competencies of two leaders in the field, we can provide unrivaled solutions for the medical device and pharmaceutical industries, unlock new opportunities in clinical trials labeling and offer a full range of solutions for customers to meet all their labeling needs.’

ABOUT THE AUTHOR

The Labels & Labeling global editorial team covers every corner of the world from Europe and the Americas, to India, Asia, Southeast Asia and Australasia with all the latest news from the label and package printing market.

See author’s profile »